Drug intelligence / Profile preview

placebo + omeprazole

Development stage: Unknown
Lead developer: P&L Development
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination of a placebo (an inert substance with no pharmacological effect) and omeprazole, a proton pump inhibitor. Omeprazole works by irreversibly inhibiting the H^+/K^+-ATPase enzyme system (the "proton pump") in gastric parietal cells, thereby reducing gastric acid secretion. It is widely used to treat gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and for the eradication of *Helicobacter pylori* infection when combined with antibiotics. The inclusion of placebo in this combination typically indicates use in clinical trials as a control or comparator arm rather than as an approved therapeutic product[1][2][3][7].

Other names: placebo + omeprazole

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on placebo + omeprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo + omeprazole.

Explore the full profile